|Bid||0.00 x 1000|
|Ask||0.00 x 1400|
|Day's range||76.92 - 78.07|
|52-week range||74.13 - 147.17|
|PE ratio (TTM)||21.72|
|Earnings date||25 Jul 2018 - 30 Jul 2018|
|Forward dividend & yield||N/A (N/A)|
|1y target est||112.98|
Several big pharma companies are about to lose patent exclusivity for blockbuster drugs. Should investors be worried?
Jim Cramer shares his take on callers' favorite stocks at lightning speed, including a medical technology company with a white-hot stock.
The Zacks Analyst Blog Highlights: Disney, Caterpillar, MetLife, Celgene and Northrop Grumman
No one expected Lisa McCormick to win New Jersey’s Democratic U.S. Senate primary over incumbent Bob Menendez. McCormick, publisher of a weekly newspaper and community news website in Rahway, was an underfunded political unknown yet managed to draw 38 percent of the vote Tuesday in a contest against a heavily favored, party-backed candidate. The narrower-than-expected margin of Menendez’s win suggests that some Democratic voters aren’t happy with the senator, whose federal corruption case was dropped by prosecutors after a mistrial in November.
The biotech sector was in focus last week due to the ASCO meet at Chicago where biotech bigwigs presented data on their oncology drugs and promising pipeline candidates.
The annual meeting of the American Society of Clinical Oncology (ASCO) in Chicago sees cancer data presentations from several drug/biotech companies about the latest developments in treating cancer.
Biotech major Celgene presents encouraging data on its oncology drugs Revlimid, Pomalyst along with other experimental therapies at the ASCO.
A number of biotechs and their pharma partners are on the move Monday morning, after presentations at the American Society of Clinical Oncology meting this weekend. Nektar Therapeutics (NKTR) is possibly the biggest loser of the bunch: The volatile stock is down 38% to $56.05 in recent trading, even as the stock rose on Friday on hopes that its news wouldn't be as bearish as first thought. Turns out, it was. H.C. Wainwright's Debjit Chattopadhyay write that its NKTR-214 drug is now a "battleground between the bulls suggesting the responses correlate with duration and is likely to be buoyed by the compelling tolerability vs. the bears arguing that the first quarter updates were the highwater mark and an artifact of patients enrolled at a center, known to deliver superior outcomes." He writes that the clinical valuation ball is "squarely in Nektar's court," which means that the next data update will be a "company defining event,"although he is still confident enough to reiterate a Buy rating on the shares.
Shares retreat after the company releases details about an upcoming phase 3 trial. Should investors be worried, or is this just market noise?
Former Celgene CEO Bob Hugin is trying to take down scandal-wracked New Jersey Sen. Bob Menendez in what could become a nasty race.
Bluebird Bio Inc. shares lifted 9% in Monday morning trade after the company and its partner, Celgene Corp. , released phase 1 clinical trial results for the CAR-T cell therapy bb2121 showing that median patients survived for 11.8 months without their cancer progressing. Celgene shares declined 0.7%. The trial focused on patients with late-stage relapsed/refractory multiple myeloma, and patients had tried several other treatments before bb2121, with a median of seven prior myeloma treatment regimens.
"There's a lot of room for a lot of product to come in," Celgene chairman and CEO Mark Alles tells CNBC.
Celgene (CELG) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
SUMMIT, N.J.--(BUSINESSWIRE)-- Updated results with liso-cel underscore potential for best-in-class CAR T profile for patients with poor prognosis Celgene Corporation (NASDAQ:CELG) today announced updated ...